Regeneron Pharmaceuticals (REGN) Other Non-Current Liabilities (2009 - 2026)

Regeneron Pharmaceuticals has reported Other Non-Current Liabilities for 18 years, with the latest figure at $2.3 billion in Q2 2026.

• On a quarterly basis, Other Non-Current Liabilities rose 34.06% year-over-year to $2.3 billion in Q2 2026; TTM through Jun 2026 was $2.3 billion, a 34.06% increase from a year earlier, with the FY2025 full-year figure at $2.0 billion, up 28.47% from the prior year.
• Other Non-Current Liabilities was $2.3 billion for Q2 2026 at Regeneron Pharmaceuticals, up from $2.1 billion in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $2.3 billion in Q2 2026, with the low at $598.6 million in Q3 2022.
• Average Other Non-Current Liabilities over 5 years is $1.3 billion, with a median of $1.2 billion recorded in 2024.
• The sharpest annual moves came in 2022 and 2024: Other Non-Current Liabilities decreased 9.66% in 2022, then soared 104.13% in 2024.
• Over 5 years, Other Non-Current Liabilities stood at $638.0 million in 2022, then surged by 33.87% to $854.1 million in 2023, then surged by 83.98% to $1.6 billion in 2024, then advanced by 28.47% to $2.0 billion in 2025, then advanced by 13.02% to $2.3 billion in 2026.
• The last three Other Non-Current Liabilities figures came in at $2.3 billion (Q2 2026), $2.1 billion (Q1 2026), and $2.0 billion (Q4 2025), per Business Quant data.